SecBot SecBot
8-K ·Filed Aug 5, 2026

QTTB

Q32 Bio Inc.
BULLISH
Impact 7/10
Horizonweeks Processed3mo ago SEC0001193125-26-333813
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

Monitor upcoming medical conference presentations for additional Week 52 data and regulatory discussions later this year, which will shape the registration-directed program's scope. The $200M cash cushion removes near-term financing overhang, allowing focus on execution.

DirectionBullish
Confidencehigh
Horizonweeks

bempikibart

◆ Mixed Named in this 8-K
Impact
Phase
Phase 2
Time to market
At least 3-5 years. Registration-directed (Phase 3) program expected to begin in H1 2027; typical Phase 3 + FDA review takes 3-4 years from initiation.
Next catalyst
None dated

What to watchThe July 13 positive Phase 2a data has already been priced in (~60% single-day surge). The next meaningful catalyst is the start of a Phase 3 registration program in H1 2027, but that is a process milestone, not a binary event. Investors should watch for FDA feedback on the registration-directed plan, potential partnership interest given the clean safety profile, and additional financing rounds as Q32 Bio will need capital to fund the pivotal trials.

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$16.49
T+0 close · Aug 5, 2026 · via day close
Latest settled
−46.21%
T+60 · $8.87
Vs SPY
−46.15%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 5 $16.49entry
  2. T+1 · 3mo ago −1.76%α −1.60% · $16.20
  3. T+5 · 3mo ago −6.79%α −7.14% · $15.37
  4. T+20 · 3mo ago −17.59%α −16.98% · $13.59
  5. T+60 · 19d ago −46.21%α −46.15% · $8.87
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Q32 Bio reported positive bempikibart 36-week topline results from the SIGNAL-AA Phase 2a trial in severe/very severe alopecia areata, demonstrating a 35.3% mean SALT reduction and 40% SALT-20 response rate (mITT) with a favorable safety profile. The company completed a $200M public offering in July 2026, extending cash runway through Phase 3 topline results from a planned registration-directed program expected to initiate in H1 2027. This filing confirms a major clinical catalyst and strong capitalization for a pivotal program.

Key Financial Metrics

EPS
−$0.44

Key Facts

  • Bempikibart achieved 35.3% mean SALT reduction from baseline at Week 36 (mITT) and 40% SALT-20 response rate; well-tolerated with no new safety signals.
  • Registration-directed program in severe/very severe AA expected to initiate in H1 2027 subject to regulatory discussions in H2 2026.
  • Completed $200M public offering in July 2026, raising gross proceeds before expenses.
  • Cash and cash equivalents were $106.3M as of June 30, 2026, plus offering proceeds expected to fund through Phase 3 topline results.
  • Venture debt of $9.7M fully repaid, net debt zero at June 30, 2026.
  • Net loss for Q2 2026 was $8.9M ($0.44 per share) vs $9.5M ($0.78 per share) in Q2 2025, improving due to lower R&D spend.

Financial Impact

Positive Phase 2a data and $200M offering materially de-risk the pivotal program; stock likely to re-rate on clinical success and extended runway.

cash positiondilution

Risk Factors

  • Phase 2a data is open-label and may not fully predict Phase 3 success; durability and safety in longer follow-up remain key.
  • Dilution from $200M equity offering pressures near-term valuation.
  • Competition from approved JAK inhibitors (e.g., Olumiant) in AA; differentiation needed on safety and durability.
  • Regulatory path timelines may slip; FDA feedback could require additional studies.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-333813
Document: qttb-20260805.htm0001193125-26-333813
Document: 0001193125-26-333813-index-headers.html0001193125-26-333813
Document: 0001193125-26-333813-index.html0001193125-26-333813
Document: 0001193125-26-333813.txt0001193125-26-333813
8-K Data (Synthetic)0001193125-26-333813

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 5, 2026